



PHG Update: December 16

Dear Valued Providers

We would like to ensure you're aware that some updates have been made to the Monoclonal Therapy Order Set (Bamlanivimab):

- The Urgent Care infusion site is now at the Miamisburg Urgent Care site (no longer at Huber Heights).
- The MVH Infusion Center is now providing this therapy, in addition to AMC and UVMC.
- The onset of symptoms has been changed from 7 days to 10 days.

Please feel free to contact us directly at **(937) 499-7441** if you have any questions.

Yours sincerely,

Matthew S. Reeves, DO, MBA
System VP, Value Based Services, Premier Health
President, Premier Health Group

IN THIS ISSUE

Updates to the Monoclonal Therapy Order Set (Bamlanivimab)

Join Dr. Colon Live Q&A Session:
Tuesday, Dec. 22 from 12:30 to 1 p.m.

Updates to the Monoclonal Therapy Order Set (Bamlanivimab)

Bamlanivimab is a monoclonal antibody for the outpatient treatment of COVID-19. While the safety and effectiveness of this investigational therapy continues to be evaluated, Bamlanivimab has been shown in clinical trials to reduce COVID-19-related hospitalization or emergency room visits in patients at high risk for disease progression within 28 days after treatment. Earlier this month, Bamlanivimab was approved by the FDA for emergency use authorization for administration to outpatients with mild to moderate cases of COVID-19. **A referral from a healthcare provider is required.**

- You must confirm that this is the patient's first positive result for SARS-CoV-2 virus.
- Patient must also:
 - Be 18 years of age or older
 - have had onset of symptoms within past 10 days
 - This must be the patient's first positive result for SARS-CoV-2 virus
 - Does not require oxygen therapy due to COVID-19 or an increase in baseline oxygen flow rate due to COVID-19 in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity
 - Not received prior dose of Bamlanivimab
 - Meet additional criteria related to age or comorbidities to receive the therapy (listed below if needed)

- Additional information continued on the next page -



- Three-part attestation must be completed. Document the following in the patient's medical record:
 - The fact sheet for patients was given to the patient or caregiver. [Click here to view the fact sheet.](#)
 - The patient was informed of alternatives to receiving authorized Bamlanivimab
 - Bamlanivimab is an unapproved drug that is authorized for use under this emergency use authorization.
- Severe adverse reactions must be reported to the FDA within 7 days. Reporting details will be forthcoming.
- **WHEN:** Go-live is **Wednesday, Dec. 2**
- **WHERE:** This will be offered at four locations
 - Atrium Medical Center Infusion Center
 - Miami Valley Hospital Infusion Center
 - Upper Valley Medical Center Infusion Center
 - Premier Health Urgent Care in Miamisburg
- **HOW:** Orders can be received by fax to **937-223-9837**. [Click here to complete the order.](#) **Please bookmark this page so you can easily access the order.**

To be treated with Bamlanivimab, at least one of the following must be present:

- ___ Greater than or equal to 65 years of age or
- ___ Body Mass Index (BMI) greater than or equal to 35 or
- ___ Chronic Kidney Disease (Stage IV or greater) or
- ___ Diabetes with A1C \geq 8 or random blood sugar > 300 mg/dL or
- ___ Immunosuppressive Condition (solid organ transplant, ESRD or ESLD, advanced HIV, active chemotherapy, chronic high dose steroids (>30mg prednisone for >30 days), use of biologic agents for treatment of underlying diseases (i.e. TNF alpha inhibitor for RA or Crohn's)

OR

Are greater than or equal to 55 years of age with one or more of the following:

- ___ Cardiovascular disease other than hypertension
- ___ Currently receiving treatment with medication for hypertension
- ___ Chronic Obstructive Pulmonary Disease, Interstitial Lung Disease, Cystic Fibrosis, or Pulmonary Fibrosis

Live Q&A Session: Tuesday, Dec. 22 from 12:30 to 1 p.m.

Join **Dr. Colon** as he discusses the Monoclonal Therapy Order Set (Bamlanivimab) and reviews the below topics:

- Monoclonal Antibody Infusion
- Order Set Change
- 10 Day Infusion Window
- Additional Infusion Sites/ED Infusions

You will receive a meeting invite that you can accept, if you would like to join the call. In addition, here is the call-in information in case the meeting invite does not come through.

Microsoft Teams meeting

Join on your computer or mobile app

[Click here to join the meeting](#)

Or call in (audio only)

[+1 937-401-2803,,735584011#](#) United States, Dayton

[\(877\) 287-6804,,735584011#](#) United States (Toll-free)

Phone Conference ID: 735 584 011#

[Find a local number](#) | [Reset PIN](#)